Jasper Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Briquilimab showed rapid, deep disease control in urticaria and asthma studies, with a favorable safety profile and differentiated mechanism. Phase II-B/III trials in CSU and CIndU are planned, with dose selection focused on balancing efficacy and safety. Equity financing is likely for upcoming studies.
-
Updated BEACON and open-label extension data show briquilimab delivers rapid, deep, and durable disease control in CSU and CIndU, with a favorable safety profile and low incidence of adverse events. Results support advancing to a phase 2b study in the second half of 2026.
Fiscal Year 2025
-
Briquilimab clinical programs in CSU and asthma advanced, with new data revealing misdiagnosis in some CSU patients and strong efficacy signals in asthma. Enhanced screening and trial designs are in place, with major data and development milestones expected in early 2024.
-
An internal investigation into the BEACON trial found that unexpected lack of efficacy was due to misdiagnosis of patients rather than drug issues, with robust PK/PD and safety confirmed. The ETESIAN study in asthma showed strong proof of concept for briquilimab, with significant biomarker and clinical improvements and a favorable safety profile.
-
No drug quality issues were found after anomalous patient responses; focus shifted to patient selection and site conduct. New enrollment and stricter criteria are in place, with major data updates from CSU, asthma, and Sindhu studies expected in early Q1 next year.
-
Briquilimab, a mast cell-depleting antibody, shows promising efficacy and safety in urticaria trials, with key data updates and investigation results expected in Q4 and early Q1. Phase IIb in CSU is planned for mid-2026, and the company has cash runway into Q3 2025.
-
Briquilimab, a KIT-targeting antibody, shows strong efficacy and safety in urticaria trials, with 180 mg every eight weeks providing rapid, sustained symptom relief and outperforming competitors. Ongoing investigations address a confounding drug lot, with expanded data and phase 2b plans expected by year-end.
-
Briquilimab demonstrated rapid, deep, and durable efficacy in CSU with strong safety in both single-dose and open-label extension studies. A compromised drug lot affected two cohorts, prompting re-dosing and additional enrollment, with robust data expected by year-end.
-
Briquilimab showed robust efficacy and safety in CINDU, with 100% clinical response at 180 mg and durable effects up to eight weeks. Safety profile was favorable, supporting an every eight-week dosing regimen, with future studies to refine optimal dosing and expand indications.
-
Briquilimab demonstrates rapid, durable efficacy and a favorable safety profile in mast cell-driven diseases, with ongoing trials in urticaria and asthma. Key data readouts and a pivotal phase II-B trial are expected in 2024–2025, targeting large unmet market needs.
-
Briquilimab, a c-Kit-targeting antibody, shows rapid and durable responses in CSU with a favorable safety profile. Upcoming BEACON and SPOTLIGHT data will inform dose selection for phase II-B trials, aiming to differentiate from competitors by depleting mast cells.
-
Briquilimab, a c-Kit targeting antibody, is showing promising results in urticaria and asthma trials, with rapid and durable responses and a favorable safety profile. Key data updates are expected midyear and in the second half of the year, with adaptive phase 2b/3 plans and strong financial interest from potential partners.
-
Briquilimab demonstrated rapid, durable, and complete symptom resolution in refractory urticaria patients, with a favorable safety profile and potential superiority over current therapies. Phase IIb trials are set for the second half of the year, with expansion into asthma and other indications planned.
-
Preliminary BEACON trial data show briquilimab achieved rapid, deep, and durable disease control in moderate to severe CSU patients refractory to standard therapies, with 100% complete response at 240 mg and a favorable safety profile. Dose selection for registrational studies will be informed by ongoing cohorts, with broader potential in other mast cell-driven diseases.
Fiscal Year 2024
-
A clinical-stage biotech is advancing a c-Kit-targeting antibody for mast cell diseases, with key CSU trial data expected in January. The program emphasizes optimal dosing for efficacy and safety, aiming to differentiate from competitors on both fronts.
-
Briquilimab demonstrated strong efficacy and durability in inducible urticaria, with a favorable safety profile potentially enhanced by its shorter half-life. Upcoming Beacon study data in chronic spontaneous urticaria could support a registrational program, while the asthma program explores broader applications.
-
Preliminary SPOTLIGHT trial data show briquilimab achieved rapid, robust clinical responses in CIndU, with 93% of patients responding and an 83% complete response rate at 120 mg. The drug was well tolerated, with no serious or severe adverse events, and demonstrated rapid, durable tryptase reduction.
-
Strong interest in mast cell therapies was evident at the summit, with briquilimab highlighted for its unique c-Kit inhibition and mast cell depletion. Key BEACON study data are expected in Q4, with safety and efficacy endpoints guiding future trial design.
-
Briquilimab, a c-Kit monoclonal antibody, is advancing in clinical trials for CSU and CIndU, with key data expected in Q4. The company aims for positive efficacy and safety results, leveraging a differentiated dosing strategy and targeting large, underserved markets.
-
Briquilimab, a c-Kit-targeting antibody, is advancing through phase II trials in urticaria and preparing for an asthma study, with key data readouts expected in Q4. Its design may offer safety and efficacy advantages over competitors, and expansion into additional indications is planned.
-
Briquilimab, a c-Kit antibody, is advancing in trials for CSU, CIndU, and asthma, with a unique mast cell depletion mechanism. Interim data for urticaria studies are expected this year, and an asthma trial will begin by year-end.